Shares of Loxo Oncology Inc. (NASDAQ:LOXO) traded up 6.1% on Thursday . The company traded as high as $28.30 and last traded at $27.64, with a volume of 84,508 shares traded. The stock had previously closed at $26.04.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday. Cowen and Company restated a “buy” rating on shares of Loxo Oncology in a research note on Wednesday, July 13th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $30.00 target price on shares of Loxo Oncology in a research note on Tuesday, April 19th. Finally, Stifel Nicolaus restated a “buy” rating and set a $36.00 target price on shares of Loxo Oncology in a research note on Monday, April 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $29.60.

The company’s market cap is $554.58 million. The company’s 50-day moving average is $24.75 and its 200 day moving average is $23.32.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.14. Equities research analysts anticipate that Loxo Oncology Inc. will post ($2.80) EPS for the current fiscal year.

In other news, major shareholder Aisling Capital Iii Lp acquired 232,558 shares of Loxo Oncology stock in a transaction dated Tuesday, May 17th. The shares were acquired at an average cost of $21.50 per share, with a total value of $4,999,997.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

A hedge fund recently bought a new stake in Loxo Oncology stock. GSA Capital Partners LLP acquired a new stake in shares of Loxo Oncology Inc. (NASDAQ:LOXO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 37,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,055,000. GSA Capital Partners LLP owned approximately 0.22% of Loxo Oncology as of its most recent SEC filing.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.